The global wearable injectors market was estimated at USD 8.80 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 18.11% from 2024 to 2030. Several key factors are driving this market, including the increasing prevalence of chronic illnesses, the growing geriatric population, and heightened concerns regarding needle stick injuries. Wearable injectors offer a more cost-effective alternative compared to other medication delivery methods. Additionally, the desire to reduce healthcare expenditures and the rising demand for continuous monitoring and home-based treatments are expected to further boost the adoption of wearable injectors.

A strong healthcare infrastructure and a rise in lifestyle-related disorders are also contributing to market expansion. However, challenges remain, such as low demand in developing economies and the high cost of wearable injectors, which could hinder growth in the coming years. Needle stick injuries (NSIs) are a significant occupational hazard for healthcare workers. According to a study by the World Health Organization (WHO) published in 2021, nearly 2 million out of 35 million healthcare professionals globally experience occupational injuries each year. Needle stick injuries increase the risk of transmitting infectious diseases, including HIV, hepatitis B, and hepatitis C.

Reports from the Centers for Disease Control and Prevention (CDC) and the European Agency for Safety and Health at Work (EU-OSHA) highlight that healthcare workers in the U.S. and Europe experience approximately 385,000 and 1,000,000 needle stick injuries, respectively. Moreover, the WHO estimates that NSIs lead to annual cases of 16,000 for hepatitis C virus (HCV), 66,000 for hepatitis B virus (HBV), and 1,000 for HIV among healthcare workers.

Gather more insights about the market drivers, restrains and growth of the Wearable Injectors Market

Type Insights

In 2023, on-body wearable injectors emerged as the dominant segment in the wearable injectors market, accounting for the largest revenue share. This surge in demand can be attributed to several factors, primarily their user-friendly design and enhanced functionality. On-body injectors are designed to be worn comfortably on the skin, typically on areas like the stomach, making them an ideal solution for continuous medication delivery. Their water-resistant nature further adds to their appeal, allowing users to maintain their daily activities without the concern of damaging the device. This convenience makes on-body injectors particularly attractive for home use, where patients can self-administer medication without frequent hospital visits.

The advantages of on-body wearable injectors extend beyond comfort. By reducing the number of necessary hospital visits, these devices can significantly decrease overall healthcare costs. This is especially important in managing chronic conditions that require ongoing treatment, as patients can administer their medication at home, promoting independence and improving their quality of life. Additionally, these injectors offer enhanced lifecycle management, allowing healthcare providers to monitor the usage and effectiveness of medication delivery over time.

Flexible dosing is another critical benefit of on-body wearable injectors. These devices can be programmed to deliver varying doses as required, catering to the specific needs of patients throughout the day. Furthermore, the automatic warming feature for refrigerated medications ensures that drugs are administered at the optimal temperature, enhancing their efficacy.

A notable innovation in this segment is the infusion set introduced by Medtronic (Ireland) in April 2021. This system allows for the continuous transport of insulin from a pump to the body over a span of up to seven days, revolutionizing diabetes management for patients by providing a more stable and consistent insulin delivery method. This advancement exemplifies the growing trend toward integrating technology with healthcare solutions to improve patient outcomes.

Conversely, off-body wearable injectors are expected to experience substantial growth, projected at a CAGR of 18.74% during the forecast period. These devices offer unique advantages that address some of the common concerns associated with wearable technology. For instance, off-body injectors eliminate the discomfort linked with the painful removal of devices, a frequent complaint among users of on-body solutions. They also tackle issues related to adhesive fitting on the skin, which can lead to skin irritation or sensitivity.

As the industry continues to innovate, significant investments are being channeled into the development of improved off-body injectors. This focus on innovation is likely to enhance the performance and user experience of these devices, making them a more attractive option for patients. Furthermore, the ongoing research and development efforts aim to address any lingering concerns associated with off-body solutions, thereby facilitating broader adoption in the market.

Order a free sample PDF of the Wearable Injectors Market Intelligence Study, published by Grand View Research.